Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

Delayed Quote. Delayed  - 08/24 05:57:30 pm
18.62 USD   +2.53%
08/03 NEKTAR THERAPEU : reports 2Q loss
08/03 NEKTAR THERAPEU : Reports Financial Results for the Second Quarter o..
07/27 NEKTAR THERAPEU : to Announce Financial Results for the Second Quart..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/11/2016 | 08:18pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Nektar Therapeutics (Nasdaq: NKTR) reported its financial results for the second quarter ended June 30, 2016 (see also Pharmaceutical Companies).

Cash and investments in marketable securities at June 30, 2016 were $274.9 million as compared to $308.9 million at December 31, 2015. This balance includes the $28.0 million payment received from AstraZeneca in April of 2016 for the sublicense of MOVENTIG(®) (naloxegol) to ProStraken in Europe. The balance does not include the $20 million upfront payment for the licensing of European rights for ONZEALD™ to Daiichi Sankyo Europe, which occurred in Q2 2016.

"We continue to execute on the development and business objectives for Nektar," said Howard W. Robin, President and CEO of Nektar. "Following our licensing agreement with Daiichi Sankyo Europe, the MAA for ONZEALD was accepted by the EMA in July, and with an accelerated assessment review granted by the CHMP, we expect a decision on the recommendation for conditional approval in Q1 2017. Our Phase 3 study of NKTR-181 in patients with chronic low back pain has now completed enrollment and is on track to have topline data in the first quarter of 2017. Finally, NKTR-214 continues to advance in its Phase 1/2 study in cancer patients at MD Anderson and Yale Cancer Centers, with initial topline data expected before the end of this year. As the first medicine designed to selectively stimulate the in vivo growth of endogenous tumor-killing T cells and natural killer cells within the tumor micro-environment, we are extremely excited about the potential of NKTR-214 to transform the immuno-oncology landscape."

Year-to-date revenue for 2016 was $91.6 million as compared to $131.5 million in the first half of 2015. Revenue in 2016 included recognition of the $28.0 million cash payment received from AstraZeneca for the sublicense of MOVENTIG® (naloxegol) to ProStrakan (Kyowa Kirin) in Europe. In addition, product sales, royalty revenue, and non-cash royalty revenue increased in the first half of 2016 compared to the first half of 2015. Revenue in the first half of 2015 included recognition of $90.0 million of the $100.0 million milestone payment from AstraZeneca following the first commercial sale of MOVANTIK in the U.S. in Q1 2015. Revenue in the second quarter of 2016 was $32.8 million as compared to $22.7 million in the second quarter of 2015.

Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $8.1 million and $14.7 million in the second quarter and first half of 2016, respectively, and $4.7 million and $8.7 million in the second quarter and first half of 2015, respectively. This non-cash royalty revenue is offset by non-cash interest expense incurred in connection with the 2012 royalty monetization of $5.0 million and $10.0 million in the second quarter and first half of 2016, respectively and $5.2 million and $10.2 million in the second quarter and first half of 2015, respectively.

Total operating costs and expenses in the first half of 2016 were $139.5 million as compared to $131.9 million in the first half of 2015. Total operating costs and expenses in the second quarter of 2016 were $71.1 million as compared to $66.1 million in the second quarter of 2015. Total operating costs and expenses increased primarily as a result of increased research and development (R&D) expense.

Research and development expense in the second quarter of 2016 was $52.4 million as compared to $45.4 million in the second quarter of 2015. For the first half of 2016, R&D expense was $101.6 million as compared to $92.4 million in the first half of 2015. R&D expense was higher in the second quarter and first half of 2016 as compared to the same periods in 2015 primarily due to expenses for the NKTR-181 Phase 3 studies and the initiation of the Phase 1/2 study of NKTR-214.

General and administrative expense was $11.0 million in the second quarter of 2016 as compared to $10.2 million in the second quarter of 2015. G&A expense in the first half of 2016 was $21.3 million as compared to $20.5 million in the first half of 2015.

Net loss in the second quarter of 2016 was $48.6 million or $0.36 loss per share as compared to $52.7 million or $0.40 loss per share in the second quarter of 2015. Net loss in the first half of 2016 was $68.1 million or $0.50 loss per share as compared to $18.8 million or $0.14 loss per share in the first half of 2015.

Keywords for this news article include: Pharmaceutical Companies, AstraZeneca, Daiichi Sankyo, Nektar Therapeutics, Investment and Finance, Marketing and Licensing Agreements.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEKTAR THERAPEUTICS
08/11 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
08/04 NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
08/03 NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
08/03 NEKTAR THERAPEUTICS : reports 2Q loss
08/03 NEKTAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2016
07/27 NEKTAR THERAPEUTICS : to Announce Financial Results for the Second Quarter 2016 ..
06/27 NEKTAR THERAPEUTICS : Submission of Matters to a Vote of Security Holders (form ..
06/16 NEKTAR THERAPEUTICS : Preclinical Data Presented at ASCO 2016 Annual Meeting Dem..
06/09 NEKTAR THERAPEUTICS : and Daiichi Sankyo Europe GmbH Sign European Licensing Agr..
06/06 NEKTAR THERAPEUTICS : Preclinical Data Presented at ASCO 2016 Annual Meeting Dem..
More news
Sector news : Biotechnology & Medical Research - NEC
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 4th Update
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 3rd Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/16 Incremental Progress At Nektar Therapeutics
08/03 Nektar Therapeutics' (NKTR) CEO Howard Robin on Q2 2016 Results - Earnings Ca..
08/03 Nektar Therapeutics misses by $0.03, beats on revenue
08/02 Notable earnings after Wednesday?s close
07/29 NEKTAR : Does It Finally Have The Midas Touch?
Advertisement
Financials ($)
Sales 2016 166 M
EBIT 2016 -113 M
Net income 2016 -147 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 14,9x
Capi. / Sales 2017 12,0x
Capitalization 2 483 M
More Financials
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 19,3 $
Spread / Average Target 6,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS7.77%2 483
INCYTE CORPORATION-24.48%15 397
CELLTRION, INC.--.--%11 401
LONZA GROUP AG14.78%10 369
QUINTILES TRANSNATIONA..10.70%9 006
ALKERMES PLC-41.42%7 047
More Results